Skip to main content
SpringerLink
Log in

Osteoporosis prevention and treatment in elderly men—a cost-effective strategy

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Center JR et al. (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297: 387–394

    Article  CAS  Google Scholar 

  2. Center JR et al. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878–882

    Article  CAS  Google Scholar 

  3. Kaufman JM et al. (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16: 510–516

    Article  CAS  Google Scholar 

  4. Lyles KW et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1809

    Article  CAS  Google Scholar 

  5. Nguyen ND et al. (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18: 1109–1117

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Bone and Mineral Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Sydney, NSW 2010, Australia j.eisman@garvan.org.au

Authors and Affiliations

  1. JA Eisman is the Director of the Bone and Mineral Research Program, Garvan Institute of Medical Research, Professor of Medicine (Adjunct), University of New South Wales, and Senior Staff Endocrinologist at St Vincent's Hospital, Sydney, Australia.,

    John A Eisman

Authors
  1. John A Eisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Eisman has participated in multicenter international studies, received research funding and/or served as a consultant for Amgen (consultant, advisory board, study investigator), deCode Genetics (consultant), Eli Lilly (consultant, advisory board, study investigator), GE Lunar (consultant), Merck, Sharp and Dohme (consultant, advisory board), Novartis (consultant, advisory board, study investigator), NPS Pharmaceuticals (consultant), Organon (consultant, study investigator), Roche-GSK (consultant, advisory board, study investigator), Sanofi-Aventis (consultant, advisory board), Servier (consultant, advisory board), and Wyeth Australia (consultant).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisman, J. Osteoporosis prevention and treatment in elderly men—a cost-effective strategy. Nat Rev Endocrinol 4, 198–199 (2008). https://doi.org/10.1038/ncpendmet0753

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0753

  • Springer Nature Limited

Search

Navigation